2021 Revenues ($USD) : $11,375,892,207 2021 Revenues (foreign currencies) : JP¥1,249,528,000,000 2021 R&D spend : $2,043,781,865 2021 Number of Employees : 15,455 Fiscal Year End : 3/31/2021 Leader : CEO Kenji Yasukawa
Tokyo-based Astellas Pharma had continued success with its Xtandi (enzalutamide) prostate-cancer-treating drug. Other bestsellers include Xospata (gilteritinib) and Padcev (enfortumab vedotin). In addition, Prograf (tacrolimus) also remains a core product in its portfolio. —BB
[Astellas Northbrook Campus. Image courtesy of the Teska Associates architectural firm that designed the campus.]
Tell Us What You Think!
You must be logged in to post a comment.